Clinical Trials
Cancer research is no longer the exclusive domain of large research universities. Willamette Valley Cancer Institute and Research Center (WVCI) is part of the largest private cancer research program in the country. Through our partnership with US Oncology, WVCI is able to offer access to a wide variety of investigational drugs through clinical trials. We are proud to offer clinical trials today that determine how cancer will be treated tomorrow.
Participation in clinical trials is optional and not all patients who desire to take part in a research study will qualify. Patients participating in research studies may benefit from the increased treatment options, access to exciting new therapies and the close personal attention received during a clinical trial.
Several of our physicians serve on US Oncology research committees to develop new protocols and determine the future studies for our network. Research conducted by WVCI physicians and US Oncology have been recognized in plenary session presentations at the American Society of Clinical Oncology, American Society of Hematology and the American Association for Cancer Research. Through these relationships, WVCI is able to offer unparalleled access to the latest breakthroughs in cancer therapy.
Current Clinical Trials
Brain Cancer - Stage IV, #09057
Phase III Double-Blind Placebo-Controlled Trial
Conventional Concurrent Chemoradiation and Adjuvant Temozolomide Plus Bevacizumab Versus Conventional Concurrent Chemoradiation and Adjuvant Temozolomide in Patients With Newly Diagnosed Glioblastoma (RTOG 0825)
Brain Cancer - Metastatic - ALL, #08182
A Randomized, Phase III, Double-Blind, Placebo-Controlled Trial Of Memantine
Prevention Of Cognitive Dysfunction In Patients Receiving Whole-Brain Radiotherapy (RTOG 0614)
Breast Cancer - Adjuvant, #07132
A Phase III Clinical Trial
Comparing the Combination of TC Plus Bevacizumab to TC Alone and to TAC for Women with Node-Positive or High-Risk Node-Negative, HER2-Negative Breast Cancer (NSABP B-46-I)
Breast Cancer - Adjuvant, #08225
A Randomised, Multi-Centre, Open-Label, Phase III Study
Adjuvant Lapatinib, Trastuzumab, Their Sequence and Their Combination in Patients with HER2/ErbB2 Positive Primary Breast Cancer
Breast Cancer - Adjuvant, #08201
A Randomized Double Blind Placebo-Controlled Trial of Neratinib (HKI-272)
Following Trastuzumab in Women With Early-Stage HER-2/neu Overexpressed/Amplified Breast Cancer
Breast Cancer - Metastatic 1st/2nd Line, #06185
Randomized Phase II Trial
Letrozole with or without Dasatinib as First and Second-Line Treatment for Hormone Receptor-Positive, HER2-Negative Post-Menopausal Breast Cancer that is Unresectable, Locally Recurrent or Metastatic
Breast Cancer - 1st Line - DCIS, #09132
A Phase III Clinical Trial
Trastuzumab Given Concurently with Radiation and Radiation Alone for Women with Her2-Postive Ductal Carcinoma In Situ (DCIS) Resected by Lumpectomy
Breast Cancer - 1st Line, #07173
A Randomized Phase III Study
Conventional Whole Breast Irradiation (WBI) Versus Partial Breast Irradiation (PBI) for Women with Stage 0, I, or II Breast Cancer (RTOG 0413)
Bladder Cancer/Urothelial Cancer - Metastatic 1st Line, #06040
Phase II Trial
Gemcitabine, Cisplatin, and Sunitinib in Patients with Advanced/Metastatic Urothelial Carcinoma
Endometrial Cancer, #09194
E7080-G000-204: An Open-Label, Single-Arm, Multicenter Phase II
Study of E7080 in Subjects with Advanced Endometrial Cancer and Disease Progression Following First-Line Chemotherapy
Endometrial Cancer - 1st Line, #10011
GOG 0249- A PHASE III TRIAL
PELVIC RADIATION THERAPY VERSUS VAGINAL CUFF BRACHYTHERAPY FOLLOWED BY PACLITAXEL/CARBOPLATIN IN PATIENTS WITH HIGH-RISK, EARLY STAGE ENDOMETRIAL CANCER
Esophageal Cancer - Locally Advanced, #08183
A Phase III Trial
Evaluating The Addition Of Cetuximab To Paclitaxel, Cisplatin, And Radiation For Patients With Esophageal Cancer Who Are Treated Without Surgery (RTOG 0436)
Leukemia - CLL, #10034
The Chronic Lymphocytic Leukemia Disease Registry
CONNECT CLL
Lung Cancer - 1st Line - NSCLC, #08044
Randomized, Open-Label, Phase 3 Study
Pemetrexed plus Carboplatin and Bevacizumab Followed by Maintenance Pemetrexed and Bevacizumab versus Paclitaxel plus Carboplatin and Bevacizumab Followed by Maintenance Bevacizumab in Patients with Stage IIIB or IV Nonsquamous Non-Small Cell Lung Cancer (H3E-MC-JMHD)
Lung Cancer - Metastatic - NSCLC, #07155
HYT105962: A randomized, phase III, open-label study
Oral topotecan plus whole-brain radiation therapy (WBRT) compared with WBRT alone in patients with brain metastases from Non-Small Cell Lung Cancer
Lung Cancer - Consolidation - NSCLC, #07178
A RANDOMIZED PHASE III COMPARISON
STANDARD- DOSE (60 Gy) VERSUS HIGHDOSE (74 Gy) CONFORMAL RADIOTHERAPY WITH CONCURRENT AND CONSOLIDATION CARBOPLATIN/PACLITAXEL +/- CETUXIMAB (IND# 103444)IN PATIENTS WITH STAGE IIIA/IIIB NON-SMALL CELL LUNG CANCER (RTOG 0617)
Lymphomas - 1st Line, #07152
C18083/3064/NL/MN: An Open-Label, Randomized, Parallel-Group Study
Bendamustine Hydrochloride and Rituximab (BR) Compared With Rituximab, Cyclophosphamide, Vincristine, and Prednisone (R-CVP) or Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in the First-Line Treatment of Patients with Advanced Indolent Non-Hodgkin’s Lymphoma (NHL) or Mantle Cell Lymphoma (MCL)
Myelomas, #09141
CONNECT (TM) MM - The Multiple Myeloma Disease Registry - Registry Protocol
https://ctms.usoncology.com/scripts/detail.asp?studynum=09141
Ovarian Cancer, #09091
A Randomized, Double-blind, Placebo-Controlled, Phase 3 Study
Assess the Efficacy and Safety of Weekly Farletuzumab (MORAb-003) in Combination with Carboplatin and Taxane in Subjects with Platinum-sensitive Ovarian Cancer in First Relapse
Prostate Cancer - Salvage, #08079
A Phase III Trial
Short Term Androgen Deprivation With Pelvic Lymph Node Or Prostate Bed Only Radiotherapy (Spport) In Prostate Cancer Patients With A Rising Psa After Radical Prostatectomy (RTOG 0534)
Prostate Cancer - 1st Line, #09200
A Phase III Prospective Randomized Trial
Dose-Escalated Radiotherapy With or Without Short-Term Androgen Deprivation Therapy for Patients With Intermediate-Risk Prostate Cancer RTOG 0815
For further information, please contact Jeanne Schaffer, Clinical Research Manager for WVCI. Jeanne can be reached in Eugene at (541) 681-4930.
